Results 71 to 80 of about 3,549 (185)

A Case of Pegfilgrastim-Induced Sweet Syndrome and Literature Review of Similar Cases

Case Reports in Oncological Medicine
Sweet's syndrome (SS), also known as acute febrile neutrophilic dermatosis, is a rare disorder characterized by painful erythematous lesions, fever, and neutrophilic dermal infiltrates.
Meghana Kesireddy, Olivia L. Makos, Dominick J. DiMaio, Jairam Krishnamurthy   +3 more
doaj   +1 more source

Real‐World Outcomes of Polatuzumab Vedotin Plus R‐CHP Versus R‐CHOP‐Based Regimens in Japanese Patients With Untreated Diffuse Large B‐Cell Lymphoma

Cancer Medicine, Volume 15, Issue 1, January 2026.
PV‐R‐CHP showed improved progression‐free and overall survivals compared to R‐CHOP‐based regimens in newly diagnosed Japanese patients with DLBCL, particularly in those with non‐GCB subtype. These results were consistent in both the overall cohort and propensity score‐matched cohorts.
Masaaki Hotta, Atsushi Satake, Ayako Iwama, Tokiko Hoshiyama, Yukie Tsubokura, Hideaki Yoshimura, Shinya Fujita, Yumiko Kono, Tomoki Ito   +8 more
wiley   +1 more source

A review of the totality of evidence supporting the development and approval of a pegfilgrastim biosimilar (LA-EP2006)

, 2022
The totality-of-evidence approach requires that similarity between a proposed biosimilar and a reference biologic is demonstrated across a range of analytical, preclinical, and clinical parameters to establish biosimilarity.
Jens Heyn (3528941), Miryana Dimova-Dobreva (12376142), Nicola Mathieson (12376154), Sanjiv S. Agarwala (12376136), Gregor Schaffar (12376148), Natalia Koptelova (12376157), Ulrich Nagl (12425883), Xinghua Guo (83000), Yu-Ming Shen (12376145), Anne Bellon (269070), Sreekanth Gattu (12376160), Martin Humphrey (12376151)   +11 more
core   +1 more source

Pegfilgrastim [PDF]

Reactions Weekly, 2020
  +6 more sources

Medical visits for chemotherapy and chemotherapy-induced neutropenia: a survey of the impact on patient time and activities

BMC Cancer, 2004
Background Patients with cancer must make frequent visits to the clinic not only for chemotherapy but also for the management of treatment-related adverse effects.
Moore Kelley, Okon Theodore A, Zhu Ling, Tauer Kurt, Fortner Barry V, Templeton Davis, Schwartzberg Lee   +6 more
doaj   +1 more source

EBV‐Negative Post–Lung Transplant Lymphoma Diagnosed via Paracentesis: A Case Report and Literature Review

Case Reports in Transplantation, Volume 2026, Issue 1, 2026.
Posttransplant lymphoproliferative disorder (PTLD) is a serious complication of solid organ transplantation. While usually Epstein–Barr virus (EBV)–positive PTLD, EBV‐negative PTLD is a distinct, typically late‐onset, and aggressive entity. A 66‐year‐old man developed progressive abdominal distension and anemia 11 years after bilateral lung ...
Pooja Suchday, Rutvik Raval, Aneeket Marwaah, Deepa Jagadeesh, Atul C. Mehta, Harleen Khatra   +5 more
wiley   +1 more source

Abstract P3-14-10: Proposed biosimilar pegfilgrastim LA-EP2006 shows similarity in pharmacokinetics and pharmacodynamics to reference pegfilgrastim in healthy subjects

, 2018
Background: Granulocyte colony-stimulating factors such as filgrastim and its long-acting version pegfilgrastim are widely used to prevent neutropenia in patients receiving chemotherapy.
R Nakov, S Gattu, J Wang, M Velinova, A Skerjanec   +4 more
core   +1 more source

A randomized double blind control trial comparing filgrastim and pegfilgrastim in cyclophosphamide peripheral blood hematopoietic stem cell mobilization [PDF]

, 2015
There are few randomized trials comparing filgrastim and pegfilgrastim in peripheral blood stem cell mobilization (PBSCM). None of the trials studied the effects of the timing of pegfilgrastim administration on the outcomes of mobilization.
HK, Liew, JT, Tan, YY, Cheng, KM, Chang, JS, Rajasuriar, Anselm, Su Ting, SG, Toh, AN, Kori, PK, Liew, SM, Tan, SP, Wong, YK, Guan, Kuan, Jew Win, SH, Lim, XY, Sim, TC, Ong   +15 more
core   +1 more source

Immunogenicity and safety of a proposed pegfilgrastim biosimilar MSB11455 versus the reference pegfilgrastim Neulasta® in healthy subjects: A randomized, double‐blind trial

Pharmacology Research & Perspectives, 2020
MSB11455 is a proposed biosimilar to the currently licensed reference pegfilgrastim (Neulasta®). This study was designed primarily to compare the immunogenicity of MSB11455 and Neulasta®.
Chris Wynne, Christian Schwabe, Emmanuelle Vincent, Armin Schueler, Janka Ryding, Martin Ullmann, Vishal Ghori, Radmila Kanceva, Michael Stahl   +8 more
doaj   +1 more source

Pegfilgrastim: Current and future perspectives in the treatment of chemotherapy-induced neutropenia

, 2006
Myeloid colony-stimulating factors (granulocyte colony-stimulating factor [G-CSF] and granulocyte-macrophage colony-stimulating factor) are commonly used in clinical practice for the prevention of anticancer chemotherapy-induced neutropenia and its ...
Schiavetto, Ilaria, Cerea G., Pedrazzoli, Paolo, Pedrazzoli P., Ricotta, Riccardo, Maugeri, Maria Rosaria, Siena S., Cerea, Giulio, Siena, Salvatore, Schiavetto I., Ricotta R.   +10 more
core   +1 more source